Navigation Links
Moffitt researchers develop process to help personalize treatment for lung cancer patients
Date:6/3/2014

TAMPA, Fla. (June 3, 2014) Moffitt Cancer Center researchers, in collaboration with the Lung Cancer Mutation Consortium, have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients. Adenocarcinoma is the most common type of lung cancer in the United States with approximately 130,000 people diagnosed each year.

The study, published in the May 21 issue of The Journal of the American Medical Association, investigated 10 highly mutated and altered genes that contribute to cancer progression, termed oncogenic driver genes, in more than 1,000 lung cancer patients. Patients with adenocarcinoma have a high probability of having mutated oncogenic driver genes in their tumors.

As new oncogenic driver genes are identified, the testing process becomes less efficient because more genes need to be analyzed in limited amounts of tumor tissue. The researchers developed a process to analyze multiple genes at one time with small amounts of patient tissue. They found that 64 percent of lung adenocarcinoma patients had at least one oncogenic driver gene.

Patients who had mutations were offered therapies targeted to their specific mutation. The researchers found that those patients who had targeted treatment against an oncogenic driver gene survived longer than those patients who did not.

"Precision medicine is the future of cancer care. We are continuing this study by attempting to profile all advanced lung adenocarcinoma patients for driver genes to match them with appropriate therapies," explained Eric B. Haura, M.D., director of Moffitt's Lung Cancer Center of Excellence. "We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer."

The researchers also plan to use this technology to study drug resistance and are developing additional platforms to guide decision making in the clinic.

Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment. This study is the first of its kind that supports the concept that the simultaneous analysis of genetic mutations is possible with the goal of delivering more personalized medicine.


'/>"/>

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: